Pharmaceutical drugs covered by patent 3,511,836. Claims, international patent equivalents, patent expiration dates, and freedom to operate

Detailed Analysis of the Scope and Claims of United States Patent 3,511,836

Introduction

United States Patent 3,511,836, titled "2,4,6,7-tetra substituted quinazolines," is a patent that focuses on the synthesis and application of specific quinazoline compounds. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Objectives

The patent, filed and granted in the 1960s, aims to provide new and useful chemotherapeutic agents, particularly those valuable in reducing blood pressure in hypertensive patients. The invention involves the synthesis of 2,4,6,7-tetra substituted quinazolines, which are a class of compounds known for their pharmacological properties[1].

Scope of the Patent

The scope of the patent encompasses the preparation, properties, and uses of the specified quinazoline compounds. Here are the key aspects:

Chemical Structure

The patent describes the synthesis of quinazoline compounds that are substituted at the 2, 4, 6, and 7 positions. These substitutions can include various groups such as amino, dimethoxy, and other functional groups that enhance the pharmacological activity of the compounds[1].

Pharmacological Use

The primary use of these compounds is as antihypertensive agents. The patent highlights their potential in treating hypertension, a condition characterized by high blood pressure.

Synthesis Methods

The patent details the methods for preparing these quinazoline compounds, including the reactants, conditions, and steps involved in the synthesis process. This is crucial for reproducing the compounds and ensuring their purity and efficacy[1].

Claims of the Patent

The claims section of the patent outlines the specific rights granted to the inventor. Here are the key claims:

Compound Claims

The patent claims the 2,4,6,7-tetra substituted quinazolines as novel compounds. These claims specify the exact structure of the compounds, including the types and positions of the substituents[1].

Method Claims

The patent also claims the methods for preparing these compounds. This includes the chemical reactions, reagents, and conditions necessary for the synthesis[1].

Use Claims

The patent claims the use of these compounds as antihypertensive agents. This includes their application in pharmaceutical formulations and their administration to patients for the treatment of hypertension[1].

Patent Landscape

To understand the broader context of this patent, it is essential to look at the patent landscape in the field of quinazoline compounds and antihypertensive agents.

Prior Art

The patent references prior art related to quinazoline compounds and their use in medicine. For instance, other patents like US Patent Numbers 3,511,836, 4,001,237, and 4,188,390 are mentioned for their relevance to the use of similar compounds as hypertensive agents[5].

Related Patents

There are several related patents that deal with similar quinazoline compounds or other antihypertensive agents. For example, US Patent Number 4,112,097 also claims the use of related compounds for similar purposes[5].

International Context

The patent landscape extends beyond the United States. International patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) can reveal similar or related patents filed in other jurisdictions[4].

Search and Analysis Tools

For a comprehensive analysis of the patent landscape, several tools and resources are available:

USPTO Patent Public Search

The USPTO's Patent Public Search tool allows for detailed searches of U.S. patents and published patent applications. This can help identify related patents and understand the evolution of the technology[4].

Global Dossier

The Global Dossier service provides access to the file histories of related applications from participating IP Offices, which can be useful in tracking the international patent family and citations related to the patent[4].

Common Citation Document (CCD)

The CCD application consolidates prior art cited by multiple offices for the family members of a patent application, facilitating a more integrated view of the global patent landscape[4].

Impact and Relevance

The patent has contributed to the development of antihypertensive medications by introducing new compounds with potential therapeutic benefits. Here are some key points:

Therapeutic Impact

The quinazoline compounds described in the patent have been valuable in the treatment of hypertension, a significant public health issue. These compounds offer alternative therapeutic options for patients.

Scientific Contribution

The patent has advanced the field of medicinal chemistry by providing new synthetic methods and pharmacologically active compounds. This has inspired further research into quinazoline derivatives and their applications.

Key Takeaways

Novel Compounds: The patent introduces 2,4,6,7-tetra substituted quinazolines as new chemotherapeutic agents.
Antihypertensive Use: The primary application of these compounds is in treating hypertension.
Synthesis Methods: Detailed methods for preparing these compounds are provided.
Patent Landscape: The patent is part of a broader landscape of quinazoline compounds and antihypertensive agents.
International Context: Similar patents exist in other jurisdictions, accessible through international patent databases.

FAQs

What is the main focus of United States Patent 3,511,836?

The main focus of the patent is the synthesis and application of 2,4,6,7-tetra substituted quinazolines as antihypertensive agents.

What are the key claims of the patent?

The patent claims the novel compounds, the methods for their preparation, and their use as antihypertensive agents.

How does this patent contribute to the field of medicinal chemistry?

The patent contributes by introducing new synthetic methods and pharmacologically active compounds, advancing the field of medicinal chemistry.

What tools can be used to analyze the patent landscape related to this patent?

Tools such as the USPTO's Patent Public Search, Global Dossier, and Common Citation Document (CCD) can be used to analyze the patent landscape.

Is this patent still in effect?

The patent has expired, as indicated by its legal status.

Sources

US3511836A - 2,4,6,7-tetra substituted quinazolines - Google Patents
U.S.C. Title 35 - PATENTS - GovInfo
Patent Claims Research Dataset - USPTO
Search for patents - USPTO
Use of alpha1-adrenoreceptor antagonists in the manufacture of a ... - EPO

Title:	2,4,6,7-tetra substituted quinazolines
Abstract:
Inventor(s):	Hans-Jurgen E Hess
Assignee:	Pfizer Inc, Pfizer Pharmaceuticals LLC
Application Number:	US690101A
Patent Claim Types: see list of patent claims
Patent landscape, scope, and claims:	Detailed Analysis of the Scope and Claims of United States Patent 3,511,836 Introduction United States Patent 3,511,836, titled "2,4,6,7-tetra substituted quinazolines," is a patent that focuses on the synthesis and application of specific quinazoline compounds. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention. Background and Objectives The patent, filed and granted in the 1960s, aims to provide new and useful chemotherapeutic agents, particularly those valuable in reducing blood pressure in hypertensive patients. The invention involves the synthesis of 2,4,6,7-tetra substituted quinazolines, which are a class of compounds known for their pharmacological properties[1]. Scope of the Patent The scope of the patent encompasses the preparation, properties, and uses of the specified quinazoline compounds. Here are the key aspects: Chemical Structure The patent describes the synthesis of quinazoline compounds that are substituted at the 2, 4, 6, and 7 positions. These substitutions can include various groups such as amino, dimethoxy, and other functional groups that enhance the pharmacological activity of the compounds[1]. Pharmacological Use The primary use of these compounds is as antihypertensive agents. The patent highlights their potential in treating hypertension, a condition characterized by high blood pressure. Synthesis Methods The patent details the methods for preparing these quinazoline compounds, including the reactants, conditions, and steps involved in the synthesis process. This is crucial for reproducing the compounds and ensuring their purity and efficacy[1]. Claims of the Patent The claims section of the patent outlines the specific rights granted to the inventor. Here are the key claims: Compound Claims The patent claims the 2,4,6,7-tetra substituted quinazolines as novel compounds. These claims specify the exact structure of the compounds, including the types and positions of the substituents[1]. Method Claims The patent also claims the methods for preparing these compounds. This includes the chemical reactions, reagents, and conditions necessary for the synthesis[1]. Use Claims The patent claims the use of these compounds as antihypertensive agents. This includes their application in pharmaceutical formulations and their administration to patients for the treatment of hypertension[1]. Patent Landscape To understand the broader context of this patent, it is essential to look at the patent landscape in the field of quinazoline compounds and antihypertensive agents. Prior Art The patent references prior art related to quinazoline compounds and their use in medicine. For instance, other patents like US Patent Numbers 3,511,836, 4,001,237, and 4,188,390 are mentioned for their relevance to the use of similar compounds as hypertensive agents[5]. Related Patents There are several related patents that deal with similar quinazoline compounds or other antihypertensive agents. For example, US Patent Number 4,112,097 also claims the use of related compounds for similar purposes[5]. International Context The patent landscape extends beyond the United States. International patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) can reveal similar or related patents filed in other jurisdictions[4]. Search and Analysis Tools For a comprehensive analysis of the patent landscape, several tools and resources are available: USPTO Patent Public Search The USPTO's Patent Public Search tool allows for detailed searches of U.S. patents and published patent applications. This can help identify related patents and understand the evolution of the technology[4]. Global Dossier The Global Dossier service provides access to the file histories of related applications from participating IP Offices, which can be useful in tracking the international patent family and citations related to the patent[4]. Common Citation Document (CCD) The CCD application consolidates prior art cited by multiple offices for the family members of a patent application, facilitating a more integrated view of the global patent landscape[4]. Impact and Relevance The patent has contributed to the development of antihypertensive medications by introducing new compounds with potential therapeutic benefits. Here are some key points: Therapeutic Impact The quinazoline compounds described in the patent have been valuable in the treatment of hypertension, a significant public health issue. These compounds offer alternative therapeutic options for patients. Scientific Contribution The patent has advanced the field of medicinal chemistry by providing new synthetic methods and pharmacologically active compounds. This has inspired further research into quinazoline derivatives and their applications. Key Takeaways Novel Compounds: The patent introduces 2,4,6,7-tetra substituted quinazolines as new chemotherapeutic agents. Antihypertensive Use: The primary application of these compounds is in treating hypertension. Synthesis Methods: Detailed methods for preparing these compounds are provided. Patent Landscape: The patent is part of a broader landscape of quinazoline compounds and antihypertensive agents. International Context: Similar patents exist in other jurisdictions, accessible through international patent databases. FAQs What is the main focus of United States Patent 3,511,836? The main focus of the patent is the synthesis and application of 2,4,6,7-tetra substituted quinazolines as antihypertensive agents. What are the key claims of the patent? The patent claims the novel compounds, the methods for their preparation, and their use as antihypertensive agents. How does this patent contribute to the field of medicinal chemistry? The patent contributes by introducing new synthetic methods and pharmacologically active compounds, advancing the field of medicinal chemistry. What tools can be used to analyze the patent landscape related to this patent? Tools such as the USPTO's Patent Public Search, Global Dossier, and Common Citation Document (CCD) can be used to analyze the patent landscape. Is this patent still in effect? The patent has expired, as indicated by its legal status. Sources US3511836A - 2,4,6,7-tetra substituted quinazolines - Google Patents U.S.C. Title 35 - PATENTS - GovInfo Patent Claims Research Dataset - USPTO Search for patents - USPTO Use of alpha1-adrenoreceptor antagonists in the manufacture of a ... - EPO More… ↓ ⤷ Try for Free

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

No data available in table
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 3,511,836

Summary for Patent: 3,511,836